Molecular driver alterations and their clinical relevance in cancer of unknown primary site

Oncotarget

Volumn 7, Issue 28, 2016, Pages 44322-44329

  Löffler, Harald ^a   Pfarr, Nicole ^a,b   Kriegsmann, Mark ^a   Endris, Volker ^a   Hielscher, Thomas ^c   Lohneis, Philipp ^d   Folprecht, Gunnar ^e   Stenzinger, Albrecht ^a,f   Dietel, Manfred ^d   Weichert, Wilko ^a,b,c,g   Krämer, Alwin ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g National Center of Tumor Diseases   (Germany)

Author keywords

Carcinoma of unknown primary; CUP; Driver mutations; Massive parallel sequencing; P53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; SMAD4 PROTEIN; CDKN2A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CARCINOGENESIS; CDKN2A GENE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SCREENING TEST; SMAD4 GENE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY;

CYCLIN-DEPENDENT KINASE INHIBITOR P18; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS, UNKNOWN PRIMARY; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 84978696555     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10035     Document Type: Article

References (38)

1. Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol. 2011; 8:701-710.
2. Neben K, Hübner G, Folprecht G, Jäger D, Krämer A. Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome. Dtsch ärztebl Int. 2008; 105:733-740.
3. Varadhachary GR, Raber MN. Carcinoma of unknown primary site. N Engl J Med. 2014; 371: 2040.
4. Löffler H, Puthenparambil J, Hielscher T, Neben K, Krämer A. Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma. Dtsch Arztebl Int. 2014; 111:481-487.
5. Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol. 2009; 36:44-51.
6. Lee J, Hahn S, Kim DW, Kim J, Kang SN, Rha SY, Lee KB, Kang JH, Park BJ. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer. 2013; 108:39-48.
7. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med. 2009; 361:1018-1020.
8. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010; 363:301-304.
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-1500.
10. Kamposioras K, Pentheroudakis G, Pavlidis N. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. Eur J Clin Invest. 2013; 43:491-500.
11. Löffler H, Krämer A. Biologic Features of CUP. In Krämer A, Löffler H (eds): Cancer of Unknown Primary. Cham: Springer International Publishing Switzerland. 2016; 27-44.
12. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol. 2003; 14:191-196.
13. Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013; 231:413-423.
14. Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015; 1:40-49.
15. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10:385-394.
16. Qiu P, Sheng J. A two-stage procedure for comparing hazard rate functions. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2008; 70:191-208.
17. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015; 349: 1483-1489.
18. Van Dyke T. p53 and tumor suppression. N Engl J Med. 2007; 356:79-81.
19. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell. 2002; 110:9-12.
20. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015; 373:1136-1152.
21. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010; 28:4473-4479.
22. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer. 1999; 80:1968-1973.
23. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001; 1:233-240.
24. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999; 18:477-485.
25. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28:622-629.
26. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996; 88: 173-182.
27. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W et al. Correlation of p53 mutations with resistance to platinumbased chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001; 7:2984-2997.
28. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell. 2006; 127:265-275.
29. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 1995; 11:210-212.
30. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321:1801-1806.
31. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007; 43:2026-2036.
32. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013; 31:217-223.
33. Bournet B, Buscail C, Muscari F, Cordelier P, Buscail L. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. Eur J Cancer. 2016; 54:75-83.
34. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014; 13:828-851.
35. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013; 13:772-787.
36. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358:1160-1174.
37. Endris V, Penzel R, Warth A, Muckenhuber A, Schirmacher P, Stenzinger A, Weichert W. Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. J Mol Diagn. 2013; 15:765-775.
38. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986; 5:255-260.